AR022323A1 - Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejo - Google Patents
Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejoInfo
- Publication number
- AR022323A1 AR022323A1 ARP000100255A ARP000100255A AR022323A1 AR 022323 A1 AR022323 A1 AR 022323A1 AR P000100255 A ARP000100255 A AR P000100255A AR P000100255 A ARP000100255 A AR P000100255A AR 022323 A1 AR022323 A1 AR 022323A1
- Authority
- AR
- Argentina
- Prior art keywords
- beta
- ras
- cyclodextrine
- sulfobutileter
- hydroxipropil
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- 239000001202 beta-cyclodextrine Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- -1 sulfobutyl Chemical group 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporciona un complejo del inhibidor de la ras-farnesiltransferasa formado del inhibidor de la ras-farnesiltransferasa o una salfarmacéuticamente aceptable del mismo, de la formula (1) en donde: n es 0 o 1; R1 se selecciona de Cl, Br, fenilo,pir idilo o ciano; R2 es aralquilo; R3 seselecciona de alquilo inferior, arilo o arilo sustituido o heterociclo; Z se selecciona de CO, SO2, CO2 o SO2NR5; R5 se selecciona de hidrogeno, alquiloinferior o alquilo sustituido; y sulfobutiléter-7-beta-ciclod extrina o 2-hidroxipropil-beta-ciclodextrina. El complejo tiene inesperadamente alta solubilidadacuosa del inhibidor de la ras-farnesiltransferasa y es util para su liberacion intravenosa en humanos que padecen cáncer. También seproporcionancomposic iones formuladas con ras-farnesiltransferasa para tratamientos antitumorales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11664799P | 1999-01-21 | 1999-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022323A1 true AR022323A1 (es) | 2002-09-04 |
Family
ID=22368422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100255A AR022323A1 (es) | 1999-01-21 | 2000-01-20 | Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejo |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6218375B1 (es) |
| EP (1) | EP1143796A4 (es) |
| JP (1) | JP2002535253A (es) |
| KR (1) | KR100708360B1 (es) |
| CN (1) | CN1219517C (es) |
| AR (1) | AR022323A1 (es) |
| AU (1) | AU772204B2 (es) |
| BG (1) | BG105666A (es) |
| BR (1) | BR9916566A (es) |
| CA (1) | CA2359646C (es) |
| CO (1) | CO5160253A1 (es) |
| CZ (1) | CZ20012601A3 (es) |
| EE (1) | EE200100382A (es) |
| GE (1) | GEP20043214B (es) |
| HK (1) | HK1038865A1 (es) |
| HU (1) | HUP0105160A3 (es) |
| ID (1) | ID30139A (es) |
| IL (1) | IL144025A (es) |
| LT (1) | LT4893B (es) |
| LV (1) | LV12712B (es) |
| MY (1) | MY119700A (es) |
| NO (1) | NO20013585L (es) |
| NZ (1) | NZ511995A (es) |
| PE (1) | PE20001419A1 (es) |
| PL (1) | PL195280B1 (es) |
| RU (1) | RU2230062C2 (es) |
| SK (1) | SK9602001A3 (es) |
| TR (1) | TR200102109T2 (es) |
| TW (1) | TWI232752B (es) |
| UA (1) | UA67825C2 (es) |
| UY (2) | UY25987A1 (es) |
| WO (1) | WO2000042849A1 (es) |
| ZA (1) | ZA200104416B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| US6566347B1 (en) * | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
| US7074921B2 (en) * | 2001-11-13 | 2006-07-11 | Bristol Myers Squibb Company | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| US6818662B2 (en) * | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| AU2003276648A1 (en) * | 2002-06-17 | 2003-12-31 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase |
| US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| CA2624463C (en) * | 2005-09-30 | 2017-02-14 | Ovation Pharmaceuticals, Inc. | Novel parenteral carbamazepine formulation |
| CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| TW200806284A (en) * | 2006-03-31 | 2008-02-01 | Alcon Mfg Ltd | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma |
| AU2007321977A1 (en) * | 2006-11-21 | 2008-05-29 | Novartis Ag | Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| PT3372605T (pt) | 2008-10-22 | 2021-12-09 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk |
| BR112012030014B1 (pt) * | 2010-05-26 | 2021-07-13 | Neurophyxia B.V. | Formulações aquosas solúveis de 2-iminobiotina |
| WO2012034038A2 (en) * | 2010-09-09 | 2012-03-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i |
| WO2013052765A1 (en) * | 2011-10-07 | 2013-04-11 | Pisces Therapeutics Llc | Malignant and non-malignant disease treatment with ras antagonists |
| CN105194685A (zh) * | 2015-10-15 | 2015-12-30 | 重庆大学 | 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂 |
| PT3389653T (pt) | 2015-12-16 | 2023-12-28 | Neurophyxia B V | 2-iminobiotina para utilização no tratamento de lesão celular cerebral |
| PH12018502124B1 (en) | 2016-04-04 | 2024-04-12 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| PT3458456T (pt) | 2016-05-18 | 2020-12-07 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US20210145816A1 (en) * | 2019-11-15 | 2021-05-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin |
| BR112022010267A2 (pt) | 2019-12-27 | 2022-08-16 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto, composição farmacêutica, e uso dos compostos |
| AU2022414970A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5630927A (en) * | 1979-08-24 | 1981-03-28 | Zeria Shinyaku Kogyo Kk | Stabilization of guaiazulene and its derivative |
| US4371673A (en) * | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| JPH1067639A (ja) * | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤 |
-
1999
- 1999-12-21 KR KR1020017009131A patent/KR100708360B1/ko not_active Expired - Fee Related
- 1999-12-21 WO PCT/US1999/030424 patent/WO2000042849A1/en not_active Ceased
- 1999-12-21 TR TR2001/02109T patent/TR200102109T2/xx unknown
- 1999-12-21 IL IL14402599A patent/IL144025A/en not_active IP Right Cessation
- 1999-12-21 PL PL99366338A patent/PL195280B1/pl not_active IP Right Cessation
- 1999-12-21 UA UA2001085843A patent/UA67825C2/uk unknown
- 1999-12-21 NZ NZ511995A patent/NZ511995A/en unknown
- 1999-12-21 RU RU2001118265/04A patent/RU2230062C2/ru not_active IP Right Cessation
- 1999-12-21 HK HK02100115.8A patent/HK1038865A1/zh unknown
- 1999-12-21 JP JP2000594323A patent/JP2002535253A/ja active Pending
- 1999-12-21 CA CA002359646A patent/CA2359646C/en not_active Expired - Fee Related
- 1999-12-21 EE EEP200100382A patent/EE200100382A/xx unknown
- 1999-12-21 HU HU0105160A patent/HUP0105160A3/hu unknown
- 1999-12-21 ID IDW00200101596A patent/ID30139A/id unknown
- 1999-12-21 AU AU23740/00A patent/AU772204B2/en not_active Ceased
- 1999-12-21 BR BR9916566-0A patent/BR9916566A/pt not_active Application Discontinuation
- 1999-12-21 GE GEAP19995955A patent/GEP20043214B/en unknown
- 1999-12-21 SK SK960-2001A patent/SK9602001A3/sk unknown
- 1999-12-21 CN CNB998157074A patent/CN1219517C/zh not_active Expired - Fee Related
- 1999-12-21 EP EP99967470A patent/EP1143796A4/en not_active Withdrawn
- 1999-12-21 CZ CZ20012601A patent/CZ20012601A3/cs unknown
- 1999-12-31 MY MYPI99005834A patent/MY119700A/en unknown
-
2000
- 2000-01-14 TW TW089100557A patent/TWI232752B/zh not_active IP Right Cessation
- 2000-01-17 US US09/483,840 patent/US6218375B1/en not_active Expired - Lifetime
- 2000-01-18 CO CO00002434A patent/CO5160253A1/es unknown
- 2000-01-20 AR ARP000100255A patent/AR022323A1/es unknown
- 2000-01-21 UY UY25987A patent/UY25987A1/es not_active Application Discontinuation
- 2000-01-21 UY UY25986A patent/UY25986A1/es unknown
- 2000-01-21 PE PE2000000046A patent/PE20001419A1/es not_active Application Discontinuation
-
2001
- 2001-05-29 ZA ZA200104416A patent/ZA200104416B/en unknown
- 2001-06-21 LT LT2001064A patent/LT4893B/lt not_active IP Right Cessation
- 2001-07-03 BG BG105666A patent/BG105666A/xx unknown
- 2001-07-04 LV LVP-01-101A patent/LV12712B/en unknown
- 2001-07-20 NO NO20013585A patent/NO20013585L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022323A1 (es) | Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejo | |
| CO5570660A2 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
| EP1490371A4 (en) | TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | |
| ES2188242T3 (es) | Derivados de quinolina. | |
| DK1377593T3 (da) | 2-Amino-propanolderivater | |
| CO5310534A1 (es) | Nuevos derivados de androstano anti-inflamatorios | |
| AR029773A1 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados y una composicion de un monomero etilenicamente insaturado preparada con el mismo | |
| ID29452A (id) | 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus | |
| BR0311132A (pt) | Inibidores do vìrus da hepatite c | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| CA2160881A1 (en) | 10,11-methanodibenzosuberane derivatives used as chemosensitizing agents | |
| ATE260275T1 (de) | Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one | |
| CO5170512A1 (es) | Derivados de tetrahidroquinolin piperidina | |
| SE0004245D0 (sv) | Novel compounds and their use | |
| AR027218A1 (es) | Inhibicion de polimerizacion de monomeros insaturados | |
| DK0640080T3 (da) | Substituerede indoler som angiotensin II antagonister | |
| TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
| ES2036948B1 (es) | Procedimiento de obtencion de compuestos derivados de piridina. | |
| ES2189151T3 (es) | Isocianatos modificados con miras a proporcionarles una propiedad tensioactiva, composicion que los contiene, revestimiento resultante. | |
| AR044175A1 (es) | Compuestos de cefemo | |
| EA200200727A1 (ru) | Новые производные индола | |
| HRP20010885B1 (en) | Ethanesulfonyl-piperidine derivatives | |
| CO5231185A1 (es) | Enaminonas heterociclicas aril-substituidas | |
| AR027035A1 (es) | Pirroles sustituidos | |
| CO5261576A1 (es) | Compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |